At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 64 enrolled
Drug / intervention
Lipopolysaccharide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Response to Inflammatory Challenge in Major Depressive Disorder
In Brief
A Phase 1 clinical trial evaluating Lipopolysaccharide and Placebo for Major Depressive Disorder. Completed, enrolled 64 participants across 1 site.
Detailed Summary
LPS Challenge in Individuals with Major Depressive Disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartSep 2017
Primary CompletionDec 2020
TodayJul 2026
First PostedMay 8, 2017
Enrollment StartSep 7, 2017
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.2 years ago
Interventions
Lipopolysaccharidebiological
Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
Placebobiological
Saline solution